APLM Live signals | Maximize Profits with Getagraph.com

BUY 112318 min ago

@ $0.675

Issued: 9 Feb 2024 @ 09:59

Return: -33.28%

Previous signal: Feb 7 - 09:54

Previous signal: Sell

Return: 4.44 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia...

Stats
Today's Volume	244 886
Average Volume	205 720
Market Cap	40.27M
EPS	$0 ( 2024-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.190
ATR14	$0.00400 (0.89%)

Volume Correlation

Long: -0.24 (neutral)

Short: -0.59 (weak negative)

Signal:(43.647) Neutral

Apollomics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Apollomics, Inc. Correlation - Currency/Commodity

0.18
( neutral )

0.03
( neutral )

0.00
( neutral )

-0.15
( neutral )

Apollomics, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.77

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.77

Financial Reports:

No articles found.

Apollomics, Inc.

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.